ArticleFrontiers in pediatrics2024
Effect of taurine supplementation on preventing ventilator-associated pneumonia in pediatrics under mechanical ventilation, a randomized controlled double-blind clinical trial.
Article in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhalation of N-Chlorotaurine Is an Effective Treatment of <italic>Aspergillus fumigatus</italic> Pneumonia in Mice.Journal of innate immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: One of the most prevalent healthcare-associated infections in the pediatric intensive care unit is ventilator-associated pneumonia (VAP). VAP not only results in prolonged hospital and intensive care unit (ICU) stays but also imposes higher costs on patients and the healthcare system. Therefore, it is essential to implement preventive measures. The lung-protective properties of taurine are recognized, and this research focuses on assessing the impact of taurine supplementation in preventing VAP. Method: This double-blind, randomized clinical trial was conducted at Namazi Hospital's PICUs. The study included pediatrics on mechanical ventilation for over 48 h. Patients were randomly divided into two groups: the taurine and placebo groups. Alongside the standard care, participants from both groups were administered taurine or placebo capsules (30 mg/kg. day) in divided doses from the day of PICU admission through PICU discharge. The incidence of VAP through clinical and laboratory evidence was considered the primary outcome. Results: Seventy-seven patients were included in the study, with 38 in the taurine group and 39 in the placebo group. VAP incidence was 7.9% in the taurine group and 64.1% in the placebo group. Taurine significantly reduced the duration of mechanical ventilation, ICU and hospital stay, and inotrope duration. The occurrence of septic shock was lower in the taurine group at 5.3%. Stepwise logistic regression showed that placebo receipt was the only risk factor for VAP, with placebo recipients being 20.8 times more likely to develop VAP. ( Conclusion: Our results showed that taurine supplementation can reduce the incidence of VAP and the duration of mechanical ventilation, ICU, and hospital stay in critically ill pediatric patients. Registration number of the clinical trial: This study received approval from the Iranian registry clinical trial, registered on 29 June 2023 (IRCT20120731010453N4, http://www.irct.ir/).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.